Hae-Young Lee, Kyung Wan Min, Kyung Ah Han, Jeong Su Kim, Jeong Cheon Ahn, Moo Hyun Kim, Jin Bae Lee, Sung-Hee Shin, Chong-Jin Kim, Kye Hun Kim, Deok-Kyu Cho, Junghyun Choi, Moo-Yong Rhee, Sung-Ho Her, Weon Kim, Jin Oh Na, Goo-Yeong Cho, Seok Yeon Kim, Gyung-Min Park, Bong-Ki Lee, Sang-Ho Jo, Byung Wan Lee, Il-Suk Sohn, Doo-Il Kim, Sang-Hyun Ihm, Sun Hwa Lee, Joong-Wha Chung, Eun Joo Cho, Jang Won Son, Seung-Jin Oh, Jin-Yong Hwang, Jin-Ok Jeong, Kyoo-Rok Han, Hyuck-Jun Yoon, Suk Min Seo, Wook-Jin Chung, Jang-Whan Bae, Jin-Ho Choi, Bok Jin Hyun, Ji Eun Cha, Seung Ji Yoo, Jinho Shin
PURPOSE: This study aimed to evaluate the efficacy and tolerability of irbesartan (IRB) and amlodipine (AML) combination therapy in patients with essential hypertension whose blood pressure (BP) was not controlled by IRB monotherapy. METHODS: Two multicenter, randomized, double-blind, placebo-controlled, phase III studies were conducted in Korea (the I-DUO 301 study and the I-DUO 302 study). After a 4-week run-in period with either 150 mg IRB (I-DUO 301 study) or 300 mg IRB (I-DUO 302 study), patients with uncontrolled BP (ie, mean sitting systolic BP [MSSBP] ≥140 mmHg to <180 mmHg and mean sitting diastolic BP <110 mmHg) were randomized to the placebo, AML 5 mg, or AML 10 mg group...
May 3, 2024: Clinical Therapeutics